Finch Therapeutics Group (FNCH) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 2 99 sessions, September 9, 2025 to March 23, 2026
- Largest daily move
- -39.2% close of March 23, 2026
- 1-year change
- -42.4% adjusted closes, September 9, 2025 to March 23, 2026
- 5-year change
- -98.4% adjusted closes, September 8, 2021 to March 23, 2026
Company Description
Finch Therapeutics Group (OTC Link: FNCH) is classified in the biotechnology industry within the Biological Products, (no Disgnostic Substances) sector and carries a market capitalization of $11.7M, ranking #6,955 among all listed U.S. companies by market cap.
FNCH has declined 47.9% over the past year. Shares last traded at $7.30.
For FY2023, Finch Therapeutics Group reported revenue of $107K with net income of -$74.8M and diluted earnings per share of -$46.59. The company operates at a net profit margin of -69863.6%.
This page collects what Stock Titan holds for FNCH, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Finch Therapeutics Group (FNCH) stock last closed at $7.30. Over the past 12 months, the stock has lost 47.9%. At a market capitalization of $11.7M, FNCH is classified as a micro-cap stock with approximately 1.6M shares outstanding.
FNCH Rankings
Latest News
Finch Therapeutics Group has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include stock split, earnings, management, clinical trial, conferences. View all FNCH news →
SEC Filings
Financial Highlights
Finch Therapeutics Group generated $107K in revenue in FY2023, operating income reached -$83.9M (-78374.8% operating margin), and net income was -$74.8M, reflecting a -69863.6% net profit margin. Diluted earnings per share stood at -$46.59. The company generated -$31.5M in operating cash flow. With a current ratio of 6.33, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Finch Therapeutics Group (FNCH) currently stands at 38 shares, down 5.0% from the previous reporting period, representing 0.0% of the float. Since September 2025, short interest has decreased by 78.7%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Finch Therapeutics Group (FNCH) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
FNCH Company Profile & Sector Positioning
Finch Therapeutics Group (FNCH) operates in the Biotechnology industry within the broader Biological Products, (no Disgnostic Substances) sector and is listed on the OTC Link.
Investors comparing FNCH often look at related companies in the same sector, including Oncotelic Therapeutics Inc (OTLC), Resverlogix (RVXCF), Institute Of Biomedical Research (MRES), ACCUSTEM SCIENCES INC (ACUT), and Cell Source Inc (CLCS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate FNCH's relative position within its industry.